aibioJupiter Neurosciences regains compliance with Nasdaq $1.00 minimum bid price rule
Tickers JUNS
Nasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning.
Key facts
- Company
- Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
- News type
- Listings
- Primary source
- Jupiter Neurosciences, Inc. 8-K (2025-07-10)
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) said it has regained compliance with the Nasdaq minimum share price standard, Rule 5550(a)(2), according to a press release dated July 10, 2025. The company said the update was also disclosed in a Form 8-K filed the same day.
What Nasdaq confirmed
On July 9, 2025, Jupiter received confirmation from the Listing Qualifications Department of Nasdaq that, as of July 3, 2025, its common stock had maintained an average closing share price of at least $1.00 for a period of thirteen days, from June 18, 2025 to July 8, 2025. The shares are no longer considered to be below the minimum bid price requirement, and Nasdaq now considers the matter closed. The release's subheading credits a positive upward trend in the company's stock price.
The release is silent on several points a reader would want. It does not give the closing prices, the date the deficiency notice was issued, the length of any compliance period or whether Jupiter considered a reverse stock split. It also does not say whether the company remains subject to any other Nasdaq requirement.
A company that sells a supplement alongside a drug candidate
Jupiter describes itself as a clinical-stage pharmaceutical company pursuing a dual-path strategy: neuroinflammation and healthy aging. It is advancing a pipeline aimed at central nervous system disorders and rare diseases while expanding into the consumer longevity market with its Nugevia product line. Both rest on JOTROL, its proprietary resveratrol formulation, which the company says has demonstrated significantly improved bioavailability. It describes Nugevia as clinical-grade science for the supplement space, supporting mental clarity, skin health and mitochondrial function.
The release says the prescription pipeline is presently at a Phase IIa in Parkinson's disease, with indications including Alzheimer's disease, Mucopolysaccharidoses Type I, Friedreich's ataxia and MELAS. It gives no trial status, enrollment figure or results. Its forward-looking statement refers to the company's ability to generate revenue from selling JOTROL products to consumers through a direct-to-consumer model, which the release does not size.
The finances behind the share price
The annual report filed on March 28, 2025 shows what the company is carrying. For 2024 and 2023, Jupiter generated no revenue from product sales and reported net losses of $2,439,625 and $4,783,689. Net cash used in operating activities was $3,911,004 in 2024, against $480,953 in 2023. Cash at the end of 2024 was $3,769,510.
Net cash from financing activities was $7,652,036 in 2024, mainly from its initial public offering and partly offset by repayments of notes payable of $2,361,677. The report says there is substantial doubt about the company's ability to continue as a going concern, citing historical recurring losses, negative operating cash flow and dependence on financings. The auditor included an explanatory paragraph on the issue for 2024 and 2023.
Jupiter says it anticipates needing to raise substantial additional capital. It warns that issuing equity would dilute stockholders, that any debt may carry restrictive covenants, and that failure to raise money could force it to delay, reduce or end development programs or sell or license rights it would prefer to keep.
The Asian strategy
The annual report says the company began business development in Asia in October 2021 and has a strong strategic interest in accelerating development and possible commercialization of JOTROL there. Chairman and chief executive Christer Rosén presented at BIOHK 2023 in Hong Kong in September 2023, and the company agreed to service agreements for business development, chemistry, manufacturing and controls, regulatory affairs and clinical trial management. It says it believes the strategy is cost effective and could speed an out-licensing deal in South-East Asia, with no assurance that it will succeed.